Given Imaging to Host Second Quarter 2013 Financial Results Conference Call on August 7, 2013

Given Imaging to Host Second Quarter 2013 Financial Results Conference Call on
August 7, 2013

YOQNEAM, Israel, July 23, 2013 (GLOBE NEWSWIRE) -- Given Imaging (Nasdaq:GIVN)
today announced that the company will host a conference call on Wednesday,
August 7, 2013 at 9:00am ET, 4:00pm Israel time to discuss second quarter 2013
financial results. The company plans to release results following the close of
U.S. financial markets on Tuesday, August 6, 2013.

To participate in the teleconference, please dial the following numbers
fifteen minutes before the call is scheduled to begin: U.S. and Canada,
888-452-4023; Israel, 1-80-924-5906. Callers in other countries should dial
719-457-2664. The call will also be webcast live at

A replay of the call will be available for two weeks on the company's website,
or until August 21, 2013, by dialing 888-203-1112. Callers in Israel should
dial 1 80 924 6038. Callers outside of the U.S. and Israel should dial
719-457-0820. The replay participant code is 8996103.

About Given Imaging Ltd.

Since pioneering the field of capsule endoscopy in 2001, Given Imaging has
become a world leader in GI medical devices, offering health care providers a
range of innovative options for visualizing, diagnosing and monitoring the
digestive system. The company offers a broad product portfolio including
PillCam® capsule endoscope for the small bowel, esophagus and colon. The
company also offers industry-leading GI functional diagnostic solutions
including ManoScan® high-resolution manometry, Bravo® capsule-based pH
monitoring, Digitrapper® pH-Z, and the SmartPill® GI monitoring systems. Given
Imaging is committed to delivering breakthrough innovations to the GI
community and supporting its ongoing clinical needs. Given Imaging's
headquarters are located in Yoqneam, Israel, with operating subsidiaries in
the United States, Germany, France, Japan, Australia, Vietnam, Hong Kong and
Brazil. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements include, but are not limited to,
projections about our business and our future revenues, expenses and
profitability. Forward-looking statements may be, but are not necessarily,
identified by the use of forward-looking terminology such as "may,"
"anticipates," "estimates," "expects," "intends," "plans," "believes," and
words and terms of similar substance. Forward-looking statements involve known
and unknown risks, uncertainties and other factors which may cause the actual
events, results, performance, circumstances or achievements of the Company to
be materially different from any future events, results, performance,
circumstances or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements include statements relating to the
Company exploring strategic alternatives and considering possible strategic
transactions involving the Company. Factors that could cause actual events,
results, performance, circumstances or achievements to differ from such
forward-looking statements include, but are not limited to, the following: (1)
our ability to develop and bring to market new products, (2) our ability to
successfully complete any necessary or required clinical studies with our
products, (3) our ability to receive regulatory clearance or approval to
market our products or changes in regulatory environment, (4) our success in
implementing our sales, marketing and manufacturing plans, (5) the level of
adoption of our products by medical practitioners, (6) the emergence of other
products that may make our products obsolete, (7) lack of an appropriate bowel
preparation materials to be used with our PillCam COLON capsule, (8)
protection and validity of patents and other intellectual property rights, (9)
the impact of currency exchange rates, (10) the effect of competition by other
companies, (11) the outcome of significant litigation, (12) our ability to
obtain reimbursement for our product from government and commercial payors,
(13) quarterly variations in operating results, (14) the possibility of armed
conflict or civil or military unrest in Israel, (15) the impact of global
economic conditions, (16) our ability to successfully integrate acquired
businesses, (17) changes and reforms in applicable healthcare laws and
regulations, (18) quality issues and adverse events related to our products,
such as capsule retention, aspiration and failure to attach or detach,
bleeding or perforation that could require us to recall products and impact
our sales and net income, and (19) other risks and factors disclosed in our
filings with the U.S. Securities and Exchange Commission, including, but not
limited to, risks and factors identified under such headings as "Risk
Factors," "Cautionary Language Regarding Forward-Looking Statements" and
"Operating Results and Financial Review and Prospects" in the Company's Annual
Report on Form 20-F for the year ended December 31, 2012. You are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Except to the extent expressly
required under applicable law, the Company undertakes no obligation to release
publicly any revisions to any forward-looking statements, to report events or
to report the occurrence of unanticipated events.

CONTACT: Fern Lazar/David Carey
         Lazar Partners Ltd.
         212 867 1768
         Israel Investor Contact:
         Nava Ladin
         Gelbart Kahana Investor Relations
Press spacebar to pause and continue. Press esc to stop.